Marie Thibault, an analyst from BTIG, reiterated the Buy rating on Abbott Laboratories (ABT – Research Report). The associated price ...

Shares of Abbott Laboratories ABT slumped 0.79% to $116.80 Wednesday, on what proved to be an all-around great trading ...

Barclays analyst Matt Miksic raised the firm’s price target on Abbott (ABT) to $149 from $143 and keeps an Overweight rating on the ...

Juries hit Mead Johnson and Abbott Laboratories with verdicts of $60 million and $495 million respectively earlier this year ...

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against the other pharma stocks. Healthcare takes the concept of 'defensive' further than almost any ...

Following the robust Q3 performance, Piper Sandler raised ABT’s price target to $133 from $131, keeping an Overweight rating ...

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

The Department of Justice announced an investigation into Abbott Laboratories' Michigan plant which was at center of a nationwide formula shortage in 2022. Abbott is recalling several of its ready ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...